カテゴリ： GlobalData, アメリカ, 企業調査

Delcath Systems Inc (DCTH)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Delcath Systems Inc (DCTH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9795
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：64
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Delcath Systems Inc (Delcath) specializes in developing percutaneous perfusion technologies to treat primary and metastatic liver cancers. Its patented drug delivery platform delivers ultra-high doses of anti-cancer drugs to the liver, while preventing them from entering the patient’s bloodstream. The company develops formulations for use with the Delcath Hepatic Delivery System (Melphalan/HDS) and to administer high dose chemotherapy to the liver. The company sells its proprietary system to deliver and filter melphalan hydrochloride in Europe under the trade name, Delcath Hepatic Chemosat Delivery System for Melphalan (Chemosat). Delcath is headquartered in New York, the US.

Delcath Systems Inc (DCTH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Delcath Systems Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Delcath Systems Inc, Medical Devices Deals, 2012 to YTD 2018 10
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deal Details 12
Equity Offering 12
Delcath Systems Plans to Raise up to USD100 Million in Public Offering of Securities 12
Delcath Systems Raises USD8.1 Million in Rights Offering of Shares 13
Delcath Systems Plans to Raise up to USD6 Million in Public Offering of Shares 15
Delcath Systems Files Registration Statement for Public Offering of Units for up to USD10 Million 16
Delcath Systems Raises USD5 Million in Public Offering of Units 17
Delcath Systems to Raise USD2.4 Million in Private Placement of Series B Preferred Shares 18
Delcath Systems Raises USD1.3 Million in Public Offering Shares and Warrants 19
Delcath Systems Raises USD7 Million in Public Offering of Units 20
Delcath Systems Raises USD3 Million in Public Offering of Shares and Warrants 22
Debt Offering 24
Delcath Systems Raises USD1.7 Million in Private Placement of 8% Notes 24
Delcath Systems Raises USD0.57 Million in Private Placement of 8% Notes Due 2019 25
Delcath Systems Raises USD35 Million in Private Placement of Notes 26
Delcath Systems Inc – Key Competitors 27
Delcath Systems Inc – Key Employees 28
Delcath Systems Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 15, 2018: Delcath announces second quarter fiscal 2018 financial results 30
May 10, 2018: Delcath Announces First Quarter 2018 Financial Results 32
Mar 16, 2018: Delcath Announces 2017 Financial Results 34
Nov 14, 2017: Delcath Announces Third Quarter 2017 Financial Results 37
Aug 08, 2017: Delcath Announces Second Quarter 2017 Financial Results 39
May 09, 2017: Delcath Announces First Quarter 2017 Financial Results 41
Mar 29, 2017: Delcath Announces 2016 Financial Results 43
Corporate Communications 45
Nov 20, 2017: Delcath Enhances Board of Directors With Appointment of Industry Veteran, Dr. Simon Pedder 45
Sep 14, 2017: Delcath Announces Accelerated Listing on OTCQB 46
Sep 13, 2017: Delcath Announces Relisting on OTCQB 47
Product News 48
12/05/2017: Favorable Results from a Multi-Center Analysis of Delcath PHP Therapy to be Published in Journal of Surgical Oncology 48
09/19/2017: Data on Delcaths CHEMOSAT System Presented at CIRSE Annual Meeting 49
05/16/2018: Delcath’s CHEMOSAT Included in German Treatment Guidelines for Melanoma Liver Metastases 50
05/14/2018: Delcath’s PHP Therapy Featured in Video Learning Session at the European Conference of Interventional Oncology 51
02/21/2017: Analysis From Two Institutions Shows Strong Tumor Response, Overall Survival Potential of Delcath Investigational PHP Therapy 52
01/18/2017: New Outcomes Data Using Delcaths Melphalan/HDS To Treat Unresectable Metastatic Ocular Melanoma To The Liver Accepted For Oral Presentation At Regional Cancer Therapies Symposium 53
01/10/2018: Delcath Announces Special Protocol Agreement Modification With FDA 54
Product Approvals 55
Mar 27, 2017: Delcath Announces Special Protocol Assessment Agreement With FDA for Pivotal Trial With Melphalan/HDS in Intrahepatic Cholangiocarcinoma 55
Clinical Trials 56
May 07, 2018: Delcath Announces Initiation of Registrational Trial of Melphalan/HDS in Intrahepatic Cholangiocarcinoma 56
May 03, 2018: Delcath Announces Another DSMB Recommendation for Phase 3 Focus Trial 57
Mar 29, 2018: Summary of Recent Published Research on Delcath’s PHP Therapy Presented at Society of Surgical Oncology Annual Symposia 58
Feb 02, 2018: Delcath Announces 500th Commercial CHEMOSAT Treatment in Europe 59
Jan 09, 2018: Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology 60
Dec 19, 2017: Delcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial 61
Feb 22, 2017: Published Review Shows Delcath Investigational PHP Doubles Overall Survival Over Other Targeted Liver Therapies 62
Jan 12, 2017: Delcath Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma Study Cohort 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Delcath Systems Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Delcath Systems Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Delcath Systems Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Delcath Systems Inc, Medical Devices Deals, 2012 to YTD 2018 10
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Delcath Systems Plans to Raise up to USD100 Million in Public Offering of Securities 12
Delcath Systems Raises USD8.1 Million in Rights Offering of Shares 13
Delcath Systems Plans to Raise up to USD6 Million in Public Offering of Shares 15
Delcath Systems Files Registration Statement for Public Offering of Units for up to USD10 Million 16
Delcath Systems Raises USD5 Million in Public Offering of Units 17
Delcath Systems to Raise USD2.4 Million in Private Placement of Series B Preferred Shares 18
Delcath Systems Raises USD1.3 Million in Public Offering Shares and Warrants 19
Delcath Systems Raises USD7 Million in Public Offering of Units 20
Delcath Systems Raises USD3 Million in Public Offering of Shares and Warrants 22
Delcath Systems Raises USD1.7 Million in Private Placement of 8% Notes 24
Delcath Systems Raises USD0.57 Million in Private Placement of 8% Notes Due 2019 25
Delcath Systems Raises USD35 Million in Private Placement of Notes 26
Delcath Systems Inc, Key Competitors 27
Delcath Systems Inc, Key Employees 28
Delcath Systems Inc, Other Locations 29
Delcath Systems Inc, Subsidiaries 29

List of Figures
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Delcath Systems Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Delcath Systems Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Delcath Systems Inc (DCTH)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Ascendance Biotechnology Inc-医療機器分野：企業M&A・提携分析
    Summary Ascendance Biotechnology Inc (Ascendance), formerly Hepregen Corp is a healthcare products provider that offers cell based assay products. The company provides vitro micro-liver cell-based platforms for use in safety testing, and pharmaceutical, biotherapeutic and diagnostic product developm …
  • CF Industries Holdings Inc (CF)：企業の財務・戦略的SWOT分析
    CF Industries Holdings Inc (CF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • BPER Banca Spa：企業のM&A・事業提携・投資動向
    BPER Banca Spa - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BPER Banca Spa Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • China Power Clean Energy Development Co Ltd (0735)：企業の財務・戦略的SWOT分析
    China Power Clean Energy Development Co Ltd (0735) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • BioClin Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary BioClin Therapeutics Inc (BioClin) is a clinical stage biotechnology company developing protein therapeutics for genetic disorders. Its lead product candidate B-701 is a human monoclonal antibody which targets the activity of FGFR3 (fibroblast growth factor receptor 3) and does not interact …
  • Polynt SpA：企業の戦略的SWOT分析
    Polynt SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Nordea Bank AB：企業の戦略・SWOT・財務情報
    Nordea Bank AB - Strategy, SWOT and Corporate Finance Report Summary Nordea Bank AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Moberg Pharma AB (MOB)：医療機器：M&Aディール及び事業提携情報
    Summary Moberg Pharma AB (Moberg Pharma), formerly Moberg Derma AB, is a pharmaceutical company. The company provides commercializes proprietary, acquired and licensed products. It provides treatment of skin diseases. Moberg Pharma treats fungal infection or psoriasis, discolored and fungus-damaged …
  • American Greetings Corporation (AM)：企業の戦略的SWOT分析
    American Greetings Corporation (AM) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Immatics Biotechnologies GmbH-製薬・医療分野：企業M&A・提携分析
    Summary Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs …
  • Penn Virginia Corporation (PVAC)：石油・ガス：M&Aディール及び事業提携情報
    Summary Penn Virginia Corp (Penn Virginia) is an independent oil and gas company. It explores, develops, and produces crude oil, Natural gas liquids (NGL), and natural gas. The company’s operations consist primarily of drilling unconventional horizontal development wells and operating producing well …
  • Exillon Energy Plc (EXI)：石油・ガス：M&Aディール及び事業提携情報
    Summary Exillon Energy Plc (Exillon) is an oil exploration and production company. The company explores, produces and develops crude oil. Its services include drilling, exploration, appraisal, development, operations, management, and production services. Exillon’s operating assets are located in two …
  • Vietnam Electricity：企業の戦略的SWOT分析
    Vietnam Electricity - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Bayshore Petroleum Corp (BSH)：企業の財務・戦略的SWOT分析
    Summary Bayshore Petroleum Corp (Bayshore Petroleum) is an oil and gas company that explores, produces, and develops natural gas and petroleum. The company develops conventional and unconventional oil and gas prospects in North America and across the world. It utilizes CCC technology for heavy oil a …
  • Rawson Oil & Gas Ltd (RAW)：石油・ガス：M&Aディール及び事業提携情報
    Summary Rawson Oil & Gas Ltd (Rawson), formerly Rawson Resources Ltd, is an oil and gas company that explores and develops crude hydrocarbon properties. The company’s projects include Cooper Basin, Otway Basin, Surat Basin, PEL154 and PEL155, Taranaki Basin, Cape Vogel Basin, North New Guinea Basin, …
  • Cardiva Medical Inc：企業の戦略的SWOT分析
    Cardiva Medical Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Abu Dhabi National Energy Co (TAQA)：電力：M&Aディール及び事業提携情報
    Summary Abu Dhabi National Energy Company (TAQA), a subsidiary of government-owned Abu Dhabi Water and Electricity Authority, is an energy and water company. It undertakes power generation; exploration, development, production and storage of oil and gas; pipelines and gas storage; and water desalina …
  • MimiVax LLC：製薬・医療：M&Aディール及び事業提携情報
    Summary MimiVax LLC (MimiVax) is a pharmaceutical company that discovers and develops immunotherapeutic vaccines and targeted therapies for the treatment of cancer. The company’s lead candidate is SurVaxM. Its SurVaxM is a cancer vaccine that stimulates a potent immune response and the survivin mole …
  • Cpp Group Plc (CPP)：企業の財務・戦略的SWOT分析
    Summary Cpp Group Plc (CPP), is a provider of bespoke products and solutions. It offers flight disruption insurance, legal protection, autocare, assetcare and mobile phone insurance. It offers services such as airport angel, card rescue, card protection, packaged accounts and travel assistance. CPP …
  • Zambon Co SpA：企業の戦略的SWOT分析
    Zambon Co SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆